Q32 Bio (QTTB) Common Equity (2017 - 2026)

Q32 Bio's Common Equity history runs 10 years deep, the most recent figure standing at $46.3 million for Q1 2026.

• On a quarterly basis, Common Equity rose 1253.79% year-over-year to $46.3 million in Q1 2026; TTM through Mar 2026 was $46.3 million, a 1253.79% increase from a year earlier, with the FY2025 full-year figure at $42.0 million, up 640.33% from the prior year.
• Common Equity climbed to $46.3 million in Q1 2026 per QTTB's latest filing, from $42.0 million in the prior quarter.
• Across five years, Common Equity topped out at $266.3 million in Q1 2022 and bottomed at -$182.9 million in Q4 2023.
• The 5-year median for Common Equity is $5.7 million (2024), against an average of $7.4 million.
• Across the five-year window, Common Equity sank 200.84% in 2025 and jumped 1253.79% in 2026, its largest moves.
• Year by year, Common Equity stood at -$130.7 million in 2022, then slumped by 39.94% to -$182.9 million in 2023, then surged by 103.1% to $5.7 million in 2024, then soared by 640.33% to $42.0 million in 2025, then advanced by 10.23% to $46.3 million in 2026.
• Per Business Quant, the three latest QTTB Common Equity figures stand at $46.3 million (Q1 2026), $42.0 million (Q4 2025), and -$18.4 million (Q3 2025).